Non-Gaussian heart rate as an independent predictor of mortality in patients with chronic heart failure.

BACKGROUND Morbidity and mortality due to chronic heart failure remain unacceptably high despite effective drug therapies, and the search for a better risk predictor is ongoing. Statistics derived from beat-to-beat fluctuations in heart rate or heart rate variability (HRV) have been used for this purpose, but the current predictability level is low or moderate at best. OBJECTIVE The purpose of this study was to evaluate whether a recently proposed non-Gaussian index of HRV is a significant and independent mortality predictor in patients with congestive heart failure (CHF). METHODS Twenty-four-hour Holter ECGs from 108 CHF patients were evaluated. Thirty-nine (36.1%) of the patients died during the follow-up period of 33 +/- 17 months. Cox proportional hazards regression analysis was performed to determine factors related to all-cause mortality. The factors evaluated derived from clinical information, including plasma brain natriuretic peptide, conventional time- and frequency-domain and fractal HRV measures, and a recently proposed non-Gaussian index lambda of HRV. RESULTS The short-term (<40 beats) non-Gaussian index lambda(40) (hazard ratio per increment of unit standard deviation 1.64, 95% confidence interval [1.23, 2.18], P <.001) and the long-term (<1,000 beats) index lambda(1000) (hazard ratio 1.42, 95% confidence interval [1.07, 2.18], P <.02), together with brain natriuretic peptide (hazard ratio 2.26, 95% confidence interval [1.45, 3.53], P <.001), are significant univariate risk predictors of mortality. In a multivariate model, lambda(40) (1.49, [1.13, 1.96], P <.005) and brain natriuretic peptide (2.39, [1.53, 3.75], P <.001) are independent predictors of the survival statistics of patients. None of the conventional HRV measures have predicted the mortality of patients in a significant and independent manner. CONCLUSION The results of this study indicate the usefulness of the short-term non-Gaussian index of HRV for risk prediction in patients with CHF.

[1]  Yoshiharu Yamamoto,et al.  Multiscale probability density function analysis: non-Gaussian and scale-Invariant fluctuations of healthy human heart rate , 2006, IEEE Transactions on Biomedical Engineering.

[2]  A L Goldberger,et al.  Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. , 2000, Circulation.

[3]  Junichiro Hayano,et al.  Critical scale invariance in a healthy human heart rate. , 2004, Physical review letters.

[4]  H. Huikuri,et al.  Fractal analysis and time- and frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failure. , 2001, The American journal of cardiology.

[5]  A. Camm,et al.  Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction , 1999, The Lancet.

[6]  Y. Gagne,et al.  Velocity probability density functions of high Reynolds number turbulence , 1990 .

[7]  J. Miller,et al.  Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. , 1987, The American journal of cardiology.

[8]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[9]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[10]  H. Stanley,et al.  Behavioral-independent features of complex heartbeat dynamics. , 2001, Physical review letters.

[11]  D. Levy,et al.  Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. , 1997, Circulation.

[12]  J. Peinke,et al.  Turbulent cascades in foreign exchange markets , 1996, Nature.

[13]  Zbigniew R Struzik,et al.  Estimator of a non-Gaussian parameter in multiplicative log-normal models. , 2007, Physical review. E, Statistical, nonlinear, and soft matter physics.

[14]  F Boomsma,et al.  Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. , 1996, Journal of the American College of Cardiology.

[15]  P. Ponikowski,et al.  Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1997, The American journal of cardiology.

[16]  H. Stanley,et al.  Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. , 1995, Chaos.

[17]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[18]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[19]  Zbigniew R Struzik,et al.  Phase transition in a healthy human heart rate. , 2005, Physical review letters.

[20]  Jeffrey M. Hausdorff,et al.  Long-range anticorrelations and non-Gaussian behavior of the heartbeat. , 1993, Physical review letters.

[21]  A. Malliani,et al.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use , 1996 .

[22]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[23]  G. Breithardt,et al.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 1996 .

[24]  E. Bacry,et al.  Modelling fluctuations of financial time series: from cascade process to stochastic volatility model , 2000, cond-mat/0005400.

[25]  J. Bigger,et al.  Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction , 1998, The Lancet.

[26]  R. Hughson,et al.  On the fractal nature of heart rate variability in humans: effects of data length and beta-adrenergic blockade. , 1994, The American journal of physiology.

[27]  J. Fleiss,et al.  Power law behavior of RR-interval variability in healthy middle-aged persons, patients with recent acute myocardial infarction, and patients with heart transplants. , 1996, Circulation.

[28]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[29]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[30]  L. Amaral,et al.  Multifractality in human heartbeat dynamics , 1998, Nature.

[31]  R. Prescott,et al.  Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). , 1998, Circulation.

[32]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[33]  M. Packer,et al.  Neurohormonal interactions and adaptations in congestive heart failure. , 1988, Circulation.